March 28th 2025
The Biotechnology Innovation Organization’s new membership survey said that 90% of US biotech companies rely on imported components for at least half of their FDA-approved products.
There are considerations companies may want to consider before seeking out a service provider.
ADC Bio to Develop New Bioconjugation Process
February 13th 2018Unlike current approaches where bioconjugation is typically done following the manufacture of the monoclonal antibody and the cytotoxic drug, the new method begins with the antibody supernatants and eliminates the need for extensive chromatographic purification.
AGC Biologics, Biomeva, CMC Biologics Combine
January 26th 2018The companies will be integrated to form the newly-branded AGC Biologics, which will specialize in customized contract development and manufacturing organization services for the scale-up and cGMP manufacture of protein-based therapeutics.